PT  - JOURNAL ARTICLE
AU  - Stewart, M W
AU  - Rosenfeld, P J
TI  - Predicted biological activity of intravitreal VEGF Trap
AID  - 10.1136/bjo.2007.134874
DP  - 2008 May 01
TA  - British Journal of Ophthalmology
PG  - 667--668
VI  - 92
IP  - 5
4099  - http://bjo.bmj.com/content/92/5/667.short
4100  - http://bjo.bmj.com/content/92/5/667.full
SO  - Br J Ophthalmol2008 May 01; 92
AB  - Aim: To compare the intravitreal binding activity of VEGF Trap with that of ranibizumab against vascular endothelial growth factor (VEGF) using a time-dependent and dose-dependent mathematical model.Methods: Intravitreal half-lives and relative equimolar VEGF-binding activities of VEGF Trap and ranibizumab were incorporated into a first-order decay model. Time-dependent VEGF Trap activities (relative to ranibizumab) for different initial doses (0.5, 1.15, 2 and 4 mg) were calculated and plotted.Results: Seventy-nine days after a single VEGF Trap (1.15 mg) injection, the intravitreal VEGF-binding activity would be comparable to ranibizumab at 30 days. After injection of 0.5, 2 and 4 mg VEGF Trap, the intravitreal VEGF-binding activities (comparable to ranibizumab at 30 days) would occur at 73, 83 and 87 days, respectivelyConclusion: On the basis of this mathematical model, VEGF Trap maintains significant intravitreal VEGF-binding activity for 10–12 weeks after a single injection.